Filing Flows › Puma Biotechnology (PBYI) › Guidance & outlook
Puma Biotechnology (PBYI) guidance and outlook
Puma Biotechnology (PBYI) raised its guidance on Nov 5, 2026: Revenue $56.0M–$58.0M for FY2026; Net income $10.0M–$12.0M for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $56.0M–$58.0M | raised |
| Net income | FY2026 | $10.0M–$12.0M | raised |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Puma Biotechnology's latest quarter
Puma Biotechnology, Q3 2026: revenue $55.1M (+1% year over year), operating margin 9.6%, net earnings $6.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Puma Biotechnology raise or lower its guidance?
Puma Biotechnology (PBYI) raised its guidance on Nov 5, 2026: Revenue $56.0M–$58.0M for FY2026; Net income $10.0M–$12.0M for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.